SCHEMBL6424253

SCHEMBL6424253

Cc1c([C@](C)(C(=O)O)C(C)C)c2c(F)c(O)ccc2n1C(=O)c1cccc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.39
AKR1C2 P52895 3/20 0.39
PIK3CD O00329 1/20 0.34
PLA2G7 Q13093 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 2/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KMT2A Q03164 2/20 0.34
TSHR P16473 2/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
NOTUM Q6P988 1/20 0.33
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6426429 0.91 AKR1C3 (0.39) AKR1C3AKR1C2PIK3CDPLA2G7SMN1; SMN2
SCHEMBL6425697 0.90 SLC6A2 (0.35) AKR1C3AKR1C2SMN1; SMN2KDM4EMAPT
SCHEMBL6426719 0.88 AKR1C3 (0.42) AKR1C3AKR1C2PLA2G7SMN1; SMN2KDM4E
SCHEMBL6424944 0.87 AKR1C3 (0.37) AKR1C3AKR1C2PIK3CDPLA2G7SMN1; SMN2
SCHEMBL6427281 0.87 CHRNA1 (0.35) AKR1C3AKR1C2KMT2AMEN1SLC22A12
SCHEMBL6426767 0.87 AKR1C3 (0.41) AKR1C3AKR1C2PLA2G7SMN1; SMN2KDM4E
SCHEMBL6425035 0.85 ABCB11 (0.34) AKR1C3AKR1C2TSHRHPGDHTT
SCHEMBL6461143 0.85 AKR1C3 (0.33) AKR1C3AKR1C2SLC22A12
SCHEMBL6423956 0.84 AKR1C3 (0.41) AKR1C3AKR1C2PLA2G7SMN1; SMN2KDM4E
SCHEMBL6425906 0.84 AKR1C3 (0.41) AKR1C3AKR1C2KDM4EMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885PIK3CD 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.